Revenue

EBITDA

Earnings

Price per share at the end of the period divided by the last reported earnings

Free Cash Flow

Soleno Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of novel therapeutics for the treatment of rare diseases. Its lead candidate is Diazoxide Choline Controlled-Release, a once-daily oral tablet for the treatment of Prader-Willi Syndrome, which is being evaluated in an ongoing Phase III clinical development program. The company was formerly known as Capnia, Inc. and changed its name to Soleno Therapeutics, Inc. in May 2017. Soleno Therapeutics, Inc. was incorporated in 1999 and is based in Redwood City, California.

Soleno Therapeutics, Inc.

The significance of a company's longevity in the market

Years since IPO

Evaluation of recent trends and improvements in the company's revenue

Revenue Growth

Assessment of recent increases in earnings per share, indicating profitability

EPS Growth

Review of the company's ability to generate free cash flow over recent periods

FCF Growth

Analysis of Return on Equity, showing how effectively the company uses equity to generate profits

Examination of debt levels using Debt/Assets and Debt/EBITDA to ensure manageable leverage

Debt

LOS ANGELES, MAY 4, 2026 /PRNEWSWIRE/ -- THE DJS LAW GROUP REMINDS INVESTORS OF A CLASS ACTION LAWSUIT AGAINST SOLENO THERAPEUTICS, INC. ("SOLENO" OR "THE COMPANY") (NASDAQ: SLNO) FOR VIOLATIONS OF 10(B) AND 20(A) OF THE SECURITIES EXCHANGE ACT OF 1934 AND RULE 10B-5 PROMULGATED THEREUNDER BY THE U.S. SECURITIES AND EXCHANGE COMMISSION. SHAREHOLDERS WHO PURCHASED SHARES OF SLNO DURING THE CLASS PERIOD LISTED ARE ENCOURAGED TO CONTACT THE FIRM REGARDING POSSIBLE LEAD PLAINTIFF APPOINTMENTS.

SOLENO THERAPEUTICS, INC. SUED FOR SECURITIES LAW VIOLATIONS - CONTACT THE DJS LAW GROUP TO DISCUSS YOUR RIGHTS - SLNO

BRAGAR EAGEL & SQUIRE, P.C. LITIGATION PARTNER BRANDON WALKER ENCOURAGES INVESTORS WHO SUFFERED LOSSES IN SOLENO (SLNO) TO CONTACT HIM DIRECTLY TO DISCUSS THEIR OPTIONS

BRAGAR EAGEL & SQUIRE, P.C. URGES SOLENO THERAPEUTICS, INC. INVESTORS WITH SIGNIFICANT LOSSES TO CONTACT THE FIRM BEFORE MAY 5TH LEAD PLAINTIFF DEADLINE

NEW YORK--(BUSINESS WIRE)--ROSEN LAW FIRM, A GLOBAL INVESTOR RIGHTS LAW FIRM, REMINDS INVESTORS ABOUT A CLASS ACTION LAWSUIT ON BEHALF OF PURCHASERS OF COMMON STOCK OF SOLENO THERAPEUTICS, INC. (NASDAQ: SLNO) BETWEEN MARCH 26, 2025 THROUGH NOVEMBER 4, 2025. SOLENO DESCRIBES ITSELF AS A BIOPHARMACEUTICAL COMPANY FOCUSED ON DEVELOPING NOVEL THERAPEUTICS FOR THE TREATMENT OF RARE DISEASES. FOR MORE INFORMATION, SUBMIT A FORM, EMAIL ATTORNEY PHILLIP KIM, OR GIVE US A CALL AT 866-767-3653. THE ALL.

SLNO DEADLINE: ROSEN LAW FIRM URGES SOLENO THERAPEUTICS, INC. (NASDAQ: SLNO) STOCKHOLDERS TO CONTACT THE FIRM FOR INFORMATION ABOUT THEIR RIGHTS

LOS ANGELES, APRIL 20, 2026 /PRNEWSWIRE/ --THE DJS LAW GROUP REMINDS INVESTORS OF A CLASS ACTION LAWSUIT AGAINST SOLENO THERAPEUTICS, INC. ("SOLENO" OR "THE COMPANY") (NASDAQ: SLNO) FOR VIOLATIONS OF 10(B) AND 20(A) OF THE SECURITIES EXCHANGE ACT OF 1934 AND RULE 10B-5 PROMULGATED THEREUNDER BY THE U.S. SECURITIES AND EXCHANGE COMMISSION. SHAREHOLDERS WHO PURCHASED SHARES OF SLNO DURING THE CLASS PERIOD LISTED ARE ENCOURAGED TO CONTACT THE FIRM REGARDING POSSIBLE LEAD PLAINTIFF APPOINTMENTS.

FOLIA HEALTH'S FULLY REMOTE, APP-BASED STUDY SPONSORED BY SOLENO THERAPEUTICS FOLLOWS PWS CAREGIVERS OVER SIX MONTHS TO CAPTURE THEIR DAILY EXPERIENCES.

FOLIA HEALTH LAUNCHES BRAVE-PWS STUDY TO BETTER UNDERSTAND THE REAL-WORLD EXPERIENCE OF PRADER-WILLI SYNDROME CAREGIVERS

INSIDERS MAY STAND TO RECEIVE SUBSTANTIAL FINANCIAL BENEFITS NOT AVAILABLE TO ORDINARY SHAREHOLDERS. THE PROPOSED TRANSACTIONS MAY CONTAIN TERMS THAT COULD LIMIT SUPERIOR COMPETING OFFERS.

ARE TERN, SLNO, WSR OBTAINING FAIR DEALS FOR THEIR SHAREHOLDERS?

NEW YORK, NEW YORK--(NEWSFILE CORP. - APRIL 14, 2026) - BERNSTEIN LIEBHARD LLP:DO YOU, OR DID YOU, OWN SHARES OF

SOLENO THERAPEUTICS, INC. (SLNO) DEADLINE ALERT BERNSTEIN LIEBHARD LLP REMINDS SOLENO THERAPEUTICS, INC. INVESTORS OF UPCOMING DEADLINE

DID YOU BUY SLNO COMMON STOCK BETWEEN MARCH 26, 2025, AND NOVEMBER 4, 2025? AFFECTED SOLENO THERAPEUTICS, INC. INVESTOR SUMMARY WHO: SOLENO THERAPEUTICS, INC. (NASDAQ: SLNO) WHAT: SECURITIES FRAUD CLASS ACTION LAWSUIT FILED CLASS PERIOD: MARCH 26, 2025, THROUGH NOVEMBER 4, 2025 DEADLINE TO SEEK LEAD PLAINTIFF STATUS: MAY 5, 2026 KEY LAWSUIT ALLEGATIONS: MATERIAL MISSTATEMENTS AND/OR OMISSIONS CONCERNING THE COMPANY'S PHASE 3 CLINICAL TRIAL PROGRAM FOR DIAZOXIDE CHOLINE EXTENDED-RELEASE TABLETS (DCCR).

SLNO INVESTOR ALERT: KESSLER TOPAZ MELTZER & CHECK, LLP ENCOURAGES SLNO INVESTORS WITH LOSSES TO CONTACT THE FIRM

LOS ANGELES, APRIL 13, 2026 /PRNEWSWIRE/ -- THE DJS LAW GROUP REMINDS INVESTORS OF A CLASS ACTION LAWSUIT AGAINST SOLENO THERAPEUTICS, INC. ("SOLENO" OR "THE COMPANY") (NASDAQ: SLNO) FOR VIOLATIONS OF 10(B) AND 20(A) OF THE SECURITIES EXCHANGE ACT OF 1934 AND RULE 10B-5 PROMULGATED THEREUNDER BY THE U.S. SECURITIES AND EXCHANGE COMMISSION. SHAREHOLDERS WHO PURCHASED SHARES OF SLNO DURING THE CLASS PERIOD LISTED ARE ENCOURAGED TO CONTACT THE FIRM REGARDING POSSIBLE LEAD PLAINTIFF APPOINTMENTS.

NEW YORK, APRIL 09, 2026 (GLOBE NEWSWIRE) -- BERNSTEIN LIEBHARD LLP: DO YOU, OR DID YOU, OWN SHARES OF SOLENO THERAPEUTICS, INC. (NASDAQ: SLNO)? DID YOU PURCHASE YOUR SHARES BETWEEN MARCH 26, 2025 AND AUGUST 4, 2025, INCLUSIVE?

VYKAT XR (DIAZOXIDE CHOLINE) IS THE FIRST AND ONLY FDA APPROVED TREATMENT FOR HYPERPHAGIA IN PRADER-WILLI SYNDROME AND REPRESENTS A TRANSFORMATIVE THERAPY EXPANDS NEUROCRINE'S HIGH-GROWTH COMMERCIAL PORTFOLIO TO THREE FIRST-IN-CLASS MEDICINES INCLUDING INGREZZA (VALBENAZINE) AND CRENESSITY (CRINECERFONT) ESTABLISHES A DURABLE PLATFORM FOR LONG-TERM REVENUE GROWTH AND VALUE CREATION, SUPPORTED BY STRONG VYKAT XR INTELLECTUAL PROPERTY ESTATE EXPECTED TO EXTEND INTO THE MID-2040S NEUROCRINE TO HOST CONFERENCE CALL AT 8:00 AM ET TODAY TO DISCUSS TRANSACTION SAN DIEGO AND REDWOOD CITY, CALIF., APRIL 6, 2026 /PRNEWSWIRE/ -- NEUROCRINE BIOSCIENCES, INC.(NASDAQ: NBIX) AND SOLENO THERAPEUTICS, INC. (NASDAQ: SLNO) TODAY ANNOUNCED THAT NEUROCRINE HAS ENTERED INTO A DEFINITIVE AGREEMENT TO ACQUIRE SOLENO FOR $53.00 PER SHARE IN CASH, REPRESENTING A TOTAL TRANSACTION EQUITY VALUE OF $2.9 BILLION.

NEUROCRINE TO ACQUIRE SOLENO THERAPEUTICS, EXPANDING ITS ENDOCRINOLOGY AND RARE DISEASE PORTFOLIO

LOS ANGELES, APRIL 6, 2026 /PRNEWSWIRE/ -- THE DJS LAW GROUP REMINDS INVESTORS OF A CLASS ACTION LAWSUIT AGAINST SOLENO THERAPEUTICS, INC. ("SOLENO" OR "THE COMPANY") (NASDAQ: SLNO) FOR VIOLATIONS OF 10(B) AND 20(A) OF THE SECURITIES EXCHANGE ACT OF 1934 AND RULE 10B-5 PROMULGATED THEREUNDER BY THE U.S. SECURITIES AND EXCHANGE COMMISSION. SHAREHOLDERS WHO PURCHASED SHARES OF SLNO DURING THE CLASS PERIOD LISTED ARE ENCOURAGED TO CONTACT THE FIRM REGARDING POSSIBLE LEAD PLAINTIFF APPOINTMENTS.

SAN FRANCISCO, APRIL 3, 2026 /PRNEWSWIRE/ --A SECURITIES CLASS ACTION LAWSUIT HAS BEEN FILED AGAINST SOLENO THERAPEUTICS, INC. (NASDAQ: SLNO) SEEKING TO REPRESENT INVESTORS WHO PURCHASED SOLENO COMMON STOCK BETWEEN MARCH 26, 2025 AND NOVEMBER 4, 2025. THE LAWSUIT FOLLOWS SOLENO'S NOVEMBER 5, 2025 REPORT OF DISAPPOINTING INFORMATION ABOUT DCCR (TRADEMARKED AS VYKAT XR), A ONCE-DAILY ORAL TABLET INTENDED TO TREAT HYPERPHAGIA.

SLNO INVESTOR ALERT: SOLENO (SLNO) SUED AFTER DCCR LAUNCH SETBACK, SHARE DROP-- HAGENS BERMAN

NEW YORK, APRIL 01, 2026 (GLOBE NEWSWIRE) -- KIRBY MCINERNEY LLP REMINDS SOLENO THERAPEUTICS, INC. (SOLENO OR THE COMPANY) (NASDAQ:SLNO) INVESTORS OF THE MAY 5, 2026 DEADLINE TO SEEK THE ROLE OF LEAD PLAINTIFF IN A PENDING FEDERAL SECURITIES CLASS ACTION. COURTS DO NOT CONSIDER APPLICATIONS FILED AFTER THIS DEADLINE. THE LEAD PLAINTIFF OVERSEES THE LITIGATION ON BEHALF OF THE CLASS AND MAY INFLUENCE KEY DECISIONS, INCLUDING LITIGATION STRATEGY AND SETTLEMENT. COURTS REGULARLY APPOINT INDIVIDUAL INVESTORS AS LEAD PLAINTIFFS, NOT ONLY INSTITUTIONS.

REMINDER: SOLENO THERAPEUTICS, INC. INVESTORS WITH SIGNIFICANT LOSSES MUST ACT BY MAY 5, 2026  CONTACT KIRBY MCINERNEY

SAN FRANCISCO, APRIL 1, 2026 /PRNEWSWIRE/ -- A SECURITIES CLASS ACTION LAWSUIT HAS BEEN FILED AGAINST SOLENO THERAPEUTICS, INC. (NASDAQ: SLNO) SEEKING TO REPRESENT INVESTORS WHO PURCHASED SOLENO COMMON STOCK BETWEEN MARCH 26, 2025 AND NOVEMBER 4, 2025. THE LAWSUIT FOLLOWS SOLENO'S NOVEMBER 5, 2025 REPORT OF DISAPPOINTING INFORMATION ABOUT DCCR (TRADEMARKED AS VYKAT XR), A ONCE-DAILY ORAL TABLET INTENDED TO TREAT HYPERPHAGIA.

SOLENO (SLNO) SUED AFTER DCCR LAUNCH SETBACK, SHARE DROP-- HAGENS BERMAN

ROBBINS LLP IS INVESTIGATING ALLEGATIONS THAT SOLENO THERAPEUTICS SLNO MISLED INVESTORS REGARDING THE VIABILITY AND EFFICACY OF ITS PHASE 3 CLINICAL TRIAL

SLNO STOCKHOLDERS HAVE RIGHTS  IF YOU LOST MONEY INVESTING IN SOLENO THERAPEUTICS, INC. CONTACT ROBBINS LLP FOR INFORMATION ABOUT RECOVERING YOUR LOSSES

DID YOU BUY SLNO COMMON STOCK BETWEEN MARCH 26, 2025, AND NOVEMBER 4, 202 5? AFFECTED SOLENO THERAPEUTICS, INC.INVESTOR SUMMARY WHO: SOLENO THERAPEUTICS, INC. (NASDAQ: SLNO) WHAT: SECURITIES FRAUD CLASS ACTION LAWSUIT FILED CLASS PERIOD: MARCH 26, 2025, THROUGH NOVEMBER 4, 2025 DEADLINE TO SEEK LEAD PLAINTIFF STATUS: MAY 5, 2026 KEY LAWSUIT ALLEGATIONS: MATERIAL MISSTATEMENTS AND/OR OMISSIONS CONCERNING THE COMPANY'S PHASE 3 CLINICAL TRIAL PROGRAM FOR DIAZOXIDE CHOLINE EXTENDED-RELEASE TABLETS ("DCCR").

LOS ANGELES, MARCH 23, 2026 /PRNEWSWIRE/ --THE DJS LAW GROUP REMINDS INVESTORS OF A CLASS ACTION LAWSUIT AGAINST SOLENO THERAPEUTICS, INC. ("SOLENO" OR "THE COMPANY") (NASDAQ: SLNO) FOR VIOLATIONS OF 10(B) AND 20(A) OF THE SECURITIES EXCHANGE ACT OF 1934 AND RULE 10B-5 PROMULGATED THEREUNDER BY THE U.S. SECURITIES AND EXCHANGE COMMISSION. SHAREHOLDERS WHO PURCHASED SHARES OF SLNO DURING THE CLASS PERIOD LISTED ARE ENCOURAGED TO CONTACT THE FIRM REGARDING POSSIBLE LEAD PLAINTIFF APPOINTMENTS.

LOS ANGELES, MARCH 20, 2026 /PRNEWSWIRE/ --THE DJS LAW GROUP REMINDS INVESTORS OF A CLASS ACTION LAWSUIT AGAINST SOLENO THERAPEUTICS, INC. ("SOLENO" OR "THE COMPANY") (NASDAQ: SLNO) FOR VIOLATIONS OF 10(B) AND 20(A) OF THE SECURITIES EXCHANGE ACT OF 1934 AND RULE 10B-5 PROMULGATED THEREUNDER BY THE U.S. SECURITIES AND EXCHANGE COMMISSION. SHAREHOLDERS WHO PURCHASED SHARES OF SLNO DURING THE CLASS PERIOD LISTED ARE ENCOURAGED TO CONTACT THE FIRM REGARDING POSSIBLE LEAD PLAINTIFF APPOINTMENTS.

LOS ANGELES, MARCH 16, 2026 /PRNEWSWIRE/ -- THE DJS LAW GROUP REMINDS INVESTORS OF A CLASS ACTION LAWSUIT AGAINST SOLENO THERAPEUTICS, INC. ("SOLENO" OR "THE COMPANY") (NASDAQ: SLNO) FOR VIOLATIONS OF 10(B) AND 20(A) OF THE SECURITIES EXCHANGE ACT OF 1934 AND RULE 10B-5 PROMULGATED THEREUNDER BY THE U.S. SECURITIES AND EXCHANGE COMMISSION. SHAREHOLDERS WHO PURCHASED SHARES OF SLNO DURING THE CLASS PERIOD LISTED ARE ENCOURAGED TO CONTACT THE FIRM REGARDING POSSIBLE LEAD PLAINTIFF APPOINTMENTS.

PHILADELPHIA, PENNSYLVANIA--(NEWSFILE CORP. - MARCH 13, 2026) - GRABAR LAW OFFICE IS INVESTIGATING CLAIMS ON BEHALF OF SHAREHOLDERS OF SOLENO THERAPEUTICS, INC. ("SOLENO" OR THE "COMPANY") (NASDAQ: SLNO). THE INVESTIGATION CONCERNS WHETHER SOLENO AND CERTAIN OF ITS EXECUTIVES VIOLATED THE FEDERAL SECURITIES LAWS BY MAKING MATERIALLY FALSE AND MISLEADING STATEMENTS AND FAILING TO DISCLOSE ADVERSE INFORMATION ABOUT THE SAFETY PROFILE AND COMMERCIAL PROSPECTS OF ITS DRUG CANDIDATE DCCR (DIAZOXIDE CHOLINE EXTENDED-RELEASE TABLETS), MARKETED AS VYKAT XR.

NOTICE TO LONG-TERM INVESTORS OF SOLENO THERAPEUTICS, INC. (SLNO): GRABAR LAW OFFICE INVESTIGATES CLAIMS ON YOUR BEHALF

LOS ANGELES, MARCH 12, 2026 /PRNEWSWIRE/ -- THE DJS LAW GROUP REMINDS INVESTORS OF A CLASS ACTION LAWSUIT AGAINST SOLENO THERAPEUTICS, INC. ("SOLENO" OR "THE COMPANY") (NASDAQ: SLNO) FOR VIOLATIONS OF 10(B) AND 20(A) OF THE SECURITIES EXCHANGE ACT OF 1934 AND RULE 10B-5 PROMULGATED THEREUNDER BY THE U.S. SECURITIES AND EXCHANGE COMMISSION. SHAREHOLDERS WHO PURCHASED SHARES OF SLNO DURING THE CLASS PERIOD LISTED ARE ENCOURAGED TO CONTACT THE FIRM REGARDING POSSIBLE LEAD PLAINTIFF APPOINTMENTS.

Soleno Therapeutics, Inc.

SLNO

Price

Financial Reports

No items found.

Press Releases

Soleno Therapeutics, Inc.

SLNO.css-1jgtvd5{-webkit-user-select:none;-moz-user-select:none;-ms-user-select:none;user-select:none;width:1em;height:1em;overflow:hidden;display:inline-block;text-align:center;-webkit-flex-shrink:0;-ms-flex-negative:0;flex-shrink:0;font-size:1.5rem;}

Price

Financial Reports

No items found.

Press Releases

SLNO